awards grant

• ...Effect of Ketaconazole 400 Mg O.D. on the Pharmacokineticof a Single 500 Mg Oral Dose of Ptk787/Zk 222584 In...
• 24 Mo 2-Blnd Randomized Multi-Center Placebo-Ctrl Prl-Grp Study Comp Eff/SAF of 0.5Mg & 1.25Mg Fingolimod (Fty720) Administrator Orally...
• 48-Wk Multi-Center Randomized 2-Blnd Prl-Grp Evaluation of Comp Eff/SAF/Tolof Exelon 10 and 15 Cm2 Patch in Pt C Alzheimer S Disease...
• 6-Month, ...Study of the SAF/Eff of Myfortic (Erl080) With Simulect, Corticosteroids & 2 Diff Lvls of Tacrolimus...
• 6wk Rndmzd Dbl-Bld Dbl-Dmmy Plcb-Ctrl Mlti-Ctr Stdy to Asseseffct of Tegaseroc 2md Tid and 6mg Tid on Dyspeptic Smptms...
• A 12 Month Double-Blind, Randomized Multicenter, Active Controlled, Parallel Group Study Comparing the Efficacy and ....
• A 12 Month Randomized Rater and Dose Blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25Mg ....
• A 12 Month, Multi-Center, Randomized, Open-Label Non- Inferiority Study Comparing the Safety and Efficacy . . .
• A 24-Month, Multi-Center, Randomized, Open-Label Non-Inferiostudy of Efficacy and Safety Comparing Two Exposures Of.....
• A 26 Week, Randomized, Active-Controlled Safety Study of Double-Blind Formoterol Fumarate in Free Combination ...
• A 26-Week Treatment, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptaive, Seamless, Parallel-Group Stud
• A 39 Week Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Effect of Fixed Dose Stalevo 100..
• A 5-Year, Prospective, Non-Interventional Multicenter Registry in Sickle Cell Disease Patients
• A Facilitated Access Program to Provide Everolimus (Rad) Formaintenance for Patients Completing Therapy in Rad Trials
• A Multi-Center, Randomized, Double-Blind Clinical Trail to Evaluate the Sfaety and Tolerability of 24 Weeks Treatment Wi
• A Multi-Center, Randomized, Double-Blind, Active-Controlled Clinical Trial to Evalate the Safety and Tolerability.......
• A Multicenter Randomized Double-Blind, Placebocontrolled Phase III Study to Evalute the Efficay Safety and ...
• A Multicenter, Randomized, Blinded Study to Assess Safety Anand Efficacy of Pasireotide Lar Vs. Octreotide Lar..........
• A Multicenter, Reandomized, Double-Blinded Active Controlled Study to Compare the Effect of 24 Weeks Treatment
• A Partially Blinded, Prospective, Randomized Multicenter Study Evaluating Efficacy, Safety and Tolerability of Oral..
• A Randomized Double Blind Placebo Controlled Event Driven Trial of Quarterly Subcutaneous Canakinumab in The............
• A Randomized Double Blind Placebo Controlled Multiple Dose Exploratory Proof of Concept Study to Assess the Safety,....
• A Randomized, Double-Blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (Som230)S.C
• A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Multicenter Study Comparing an Eight-Week Treatment..
• A Randomized, Multicenter, Double-Blind, Placebo-Controlled,Parallel-Grouop, 24-Week, Pilot Study to Assess the Efficacy
• A Rdmz, Dbl-Bld, Pla-Cont, Par-Group, Multi-Center Study to Evaluate the Efficacy & Saftey of Dnk333 35 Mg B.I.D. Given Orall
• A Single Arm. Openlabel Muticenter Study Evaluating the Longterm Safety Tolerabiity and Efficacy of 0.5Mg Fingolimod
• An Open Labe 52-Week Study to Evaluate the Safety & Efficacyof Tegaserod (6 Mg B.E.D. and 12 Mg O.D.) Given Orally for T
• Clinician and Patient Characteristics Associated With Clinical Inertia in Blood Pressure Control
• Cspp100A2366, Entitled a 104 Week Randomized Double-Blind Placebo-Controlled Parallel-Group Multicenter Study To......
• Cyclosporine in Hepatitis C Viral Clearance Following Liver Transplant
• Healthcare Management Research Agreement Task 24/03
• Novartis Pharmaceuticals Trial Entitled: a 26-Week Treatmentmulticenter, Randomized, Double-Blind, Double Dummy
• Outcomes Related to Induction Therapy and Outcome of Neoral vs Prograf
• Phase I, Open Label, Clinical Study to Determine the Maximumtolerated Dose (Mtd) of Oral Dovitinib (Tki258) When Given..
• Randomized 2Blnd Plcb-Ctrl Prll-Grp Study to Det Wh in Pt C Type 2Diab At Hi Risk for Cardiovasc/Renal Events, Aliskiren, ...
• Randomized Opn-Lbl Multi-Center Phs3 Trial to Assess SAF of Tobramycin Inhalation Powder Comp to Tobi in Cystic Fibrosis Subjects
• Re Gist Ry
• Resource Use, Costs, and Persistency of Iron Chelation Therapy for Sickle Cell Disease Patients in the Florida Medicaid
• Sustain: a Multi-Center Randomized Open Label Controlled Study to Compare the Sustained Virological Response During..
• The Effect of Omalizumab on Airway Responsiveness to Adenosing with Poorly Controlled Asthma
• The Impact of Copayment on Healthcare Costs, Utilization, and Care Protocol Adherence: a Study of an Innovative(Task 2)
• Unveiling Novel Signaling Mechanisms of Serelaxin in Vasculature